Arcadia Biosciences announces annual shareholder meeting

• Arcadia Biosciences will hold its 2026 annual stockholder meeting virtually on Sept. 10, 2026.
• Shareholders will vote to re-elect Gregory D. Waller as a Class II director.
• Items include approval of potential common-stock issuance tied to Series A-1 Preferred Investment Options from the June 12, 2026 private placement.
• Votes are also scheduled on the 2026 Omnibus Equity Incentive Plan, a reverse stock split of 1-for-2 to 1-for-10, executive pay, auditor ratification, adjournment authority.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcadia Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-328642), on July 31, 2026, and is solely responsible for the information contained therein.